Evidence map›Paper›PMID 30804189›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

SHARPIN at the nexus of integrin, immune, and inflammatory signaling in human platelets.

Ana Kasirer-Friede, Winson Tjahjono, Koji Eto, Sanford J Shattil

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting integrin pathways: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ana Kasirer-FriedeHematology-Oncology Division, Department of Medicine, University of California, San Diego, La Jolla, CA 92093; akasirerfriede@ucsd.edu sshattil@ucsd.edu.
Winson TjahjonoHematology-Oncology Division, Department of Medicine, University of California, San Diego, La Jolla, CA 92093.
Koji EtoCenter for iPS Cell Research and Application, Kyoto University, 606-8507 Kyoto, Japan.
Sanford J ShattilHematology-Oncology Division, Department of Medicine, University of California, San Diego, La Jolla, CA 92093; akasirerfriede@ucsd.edu sshattil@ucsd.edu.
University of California, San Diego · USKyoto University · JP

Funding

The Interaction of TPO and Integrins in Hematopoiesis CellsP01HL078784 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2005 to 2019
$28.3M
Discoveries at the Crossroads of Integrin and Inflammatory Signaling in PlateletsR01HL056595 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHATTIL, SANFORD J · 1996 to 2020
$7.5M
NHLBI NIH HHS P01 HL078784NHLBI NIH HHS R01 HL056595
6 · The paper itself

Abstract

Platelets mediate primary hemostasis, and recent work has emphasized platelet participation in immunity and inflammation. The function of the platelet-specific integrin αIIbβ3 as a fibrinogen receptor in hemostasis is well defined, but the roles of αIIbβ3 or integrin-associated proteins in nonhemostatic platelet functions are poorly understood. Here we show that human platelets express the integrin-associated protein SHARPIN with functional consequences. In leukocytes, SHARPIN interacts with integrin α cytoplasmic tails, and it is also an obligate member of the linear ubiquitin chain assembly complex (LUBAC), which mediates Met1 linear ubiquitination of proteins leading to canonical NF-κB activation. SHARPIN interacted with αIIb in pull-down and coimmunoprecipitation assays. SHARPIN was partially localized, as was αIIbβ3, at platelet edges, and thrombin stimulation induced more central SHARPIN localization. SHARPIN also coimmunoprecipitated from platelets with the two other proteins comprising LUBAC, the E3 ligase HOIP and HOIL-1. Platelet stimulation with thrombin or inflammatory agonists, including lipopolysaccharide or soluble CD40 ligand (sCD40L), induced Met1 linear ubiquitination of the NF-κB pathway protein NEMO and serine-536 phosphorylation of the p65 RelA subunit of NF-κB. In human megakaryocytes and/or platelets derived from induced pluripotent stem (iPS) cells, SHARPIN knockdown caused increased basal and agonist-induced fibrinogen binding to αIIbβ3 as well as reduced Met1 ubiquitination and RelA phosphorylation. Moreover, these SHARPIN knockdown cells exhibited increased surface expression of MHC class I molecules and increased release of sCD40L. These results establish that SHARPIN functions in the human megakaryocyte/platelet lineage through protein interactions at the nexus of integrin and immune/inflammatory signaling.

Indexed as

Signal TransductionBlood PlateletsCell LineageGene Knockdown TechniquesHomeostasisHumansI-kappa B KinaseInduced Pluripotent Stem CellsInflammationMegakaryocytesModels, BiologicalNF-kappa BPlatelet Membrane Glycoprotein IIbProtein BindingUbiquitinUbiquitinationI-kappa B KinaseIKBKG protein, humanNF-kappa BPlatelet Membrane Glycoprotein IIbRNF31 protein, humanSHARPIN protein, humanUbiquitinUbiquitin-Protein LigasesUbiquitinshemostasisinflammationintegrinLUBACplatelet

Identifiers

PMID30804189
PMCPMC6421413
OpenAlexW2917815814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.